Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4. - Wikidata - awgldk - TriplyDB

Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4.

Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4.

http://www.wikidata.org/entity/Q35556797

about

(125)I-labeled anti-bFGF monoclonal antibody inhibits growth of hepatocellular carcinoma Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors Antibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy.An anti-H5N1 influenza virus FcDART antibody is a highly efficacious therapeutic agent and prophylactic against H5N1 influenza virus infection Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development.Off-target platelet activation in macaques unique to a therapeutic monoclonal antibody.Is fibroblast growth factor receptor 4 a suitable target of cancer therapy?Multiplex epitope mapping using bacterial surface display reveals both linear and conformational epitopes.A high-affinity native human antibody neutralizes human cytomegalovirus infection of diverse cell types Augmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies.Assessing kinetic and epitopic diversity across orthogonal monoclonal antibody generation platforms Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges.Immunotherapy targets in pediatric cancer.Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration.ADME of biologics-what have we learned from small molecules?Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge.Tuning the specificity of a Two-in-One Fab against three angiogenic antigens by fully utilizing the information of deep mutational scanning.Evaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey Pharmacokinetics Humanization of high-affinity antibodies targeting glypican-3 in hepatocellular carcinoma Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?Investigative safety science as a competitive advantage for Pharma.Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics.Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins.Roles of FGFR in oral carcinogenesis.Chemopreventive and hepatoprotective effects of Epigallocatechin-gallate against hepatocellular carcinoma: role of heparan sulfate proteoglycans pathway.Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates.Engineering the surface properties of a human monoclonal antibody prevents self-association and rapid clearance in vivo.A strategy for risk mitigation of antibodies with fast clearance.Practical considerations for chimeric antigen receptor design and delivery.Anti-neuropilin-1 (MNRP1685A): unexpected pharmacokinetic differences across species, from preclinical models to humans.Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody.Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics.Single cell protein analysis for systems biology

P2860

Q24658608-85C5C94E-39F3-4137-9F33-1E7CD1C15144 Q26998790-CBCD533C-923C-4630-9929-18F296699324 Q30275229-2DA0B27F-2CC0-4F45-B950-BA5B796DB1B6 Q30371674-B082EE8F-9E09-45A0-8E01-B4F835DB5906 Q30930928-915A1491-5476-4BA2-BC1D-F96878E8197B Q33161260-5F29C2C7-74D5-4AD0-936D-ABFD0EDBAB29 Q33751398-4D5A518F-567C-488B-915F-96754F1E35D8 Q34438836-7412BF77-E56D-4319-9A84-F9E8C34D596D Q35076970-D567F5E3-1B53-46E7-8A7F-B8142F759797 Q35856534-16F500DE-F8E0-4485-A0A3-08DAE153A29C Q35864980-D82131A9-47E8-481A-922D-CB39ADD51473 Q35929084-11E827C0-DA6A-4E39-8E29-30B760A34FEA Q35971029-4FF5C3BA-BEAB-4578-8E65-258665A76E69 Q35992509-E8E55450-B27B-4293-919F-135B499C46DB Q36065589-CFFF2D8D-7F76-4554-83E4-ECAB84EDF9C0 Q36153295-F8B9DB9A-BFF1-4FC0-BF97-6A3A7C7325DE Q36214515-D99CE627-D6D7-49B6-A533-93F3A97F75E9 Q36215733-55399488-D26E-452F-9D7E-EBD78E9F1E3C Q36393842-D5FD58DD-D981-492C-959A-DD639DB9E48A Q36444225-F0A989DC-537B-4262-BC61-0E8D005C375B Q37282388-7950DF34-7717-4712-90F1-3DC59E5EC2B6 Q37976121-8ECD21A5-75BB-4F2D-88AC-06C02E3C79A1 Q38024403-A50AB896-6BDE-4418-8FD8-3C7324BCC343 Q38587550-67EB90A0-D1BD-4C44-A67D-13DFA5EABB71 Q38831148-01775B28-4898-4579-A30A-877A969B0013 Q38842890-C5E1D73E-2DC5-48C0-9BD8-D9C9F6A750F5 Q39017090-F4C7FCE2-A5C5-4545-BBE3-3D79E402C715 Q39277950-583F8662-0F6C-4FED-8B0C-674C4DF1DBAD Q39496098-F156DBC0-7AD2-4FD1-BF13-624CF697A454 Q41575498-312F35E1-7371-4A57-ADF7-17A125E38E37 Q45868559-4750E1C6-5D39-4E36-9F5B-2594593AE0BF Q46211189-8CA3AAF3-3F4F-488F-81B1-7C020B1EA021 Q46866013-2AA29447-F90F-4847-B948-82F359859B89 Q54979517-245632DB-7B23-4882-BD7F-B798F512E60A Q58708337-2BC842D7-9190-46E8-AEEA-7FC4C081426F

P2860

Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4.

http://www.wikidata.org/entity/Q35556797

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Highly specific off-target bin ...... tibody against FGF receptor 4.

@ast

Highly specific off-target bin ...... tibody against FGF receptor 4.

@en

type

label

Highly specific off-target bin ...... tibody against FGF receptor 4.

@ast

Highly specific off-target bin ...... tibody against FGF receptor 4.

@en

prefLabel

Highly specific off-target bin ...... tibody against FGF receptor 4.

@ast

Highly specific off-target bin ...... tibody against FGF receptor 4.

@en

P1433

Q35556797-B92E2434-541D-4470-A2CC-58CA038F80F6

P1476

Q35556797-D5F708E1-B7C4-423F-8A6D-AB8DDC9DB681

P2093

Q35556797-42BE1F47-CE9D-4B1F-8A59-9B9E50CF32F1

Q35556797-55363711-95C5-4924-ABA8-2BC014FA60E4

Q35556797-624BA6EF-6A8F-4A73-B18A-914E3404636C

Q35556797-72B771F9-AC63-47E6-AC9A-1EEBB800FC0C

Q35556797-7930D300-C4A0-4977-BA0E-78F246A76198

Q35556797-9440FC68-0F5D-44C9-9343-69001E16492E

Q35556797-959F38F0-F19B-43A8-BEFE-C85B34083D74

Q35556797-CF2EDC96-D112-4D70-9AAD-30346DF40D73

Q35556797-E3648CBB-635D-4CB1-91FE-C5018A36F73D

P2860

Q35556797-0EF3CD20-3B2F-42C9-82BF-46AE8E2453A4

Q35556797-24BF7E99-58E1-4CA5-924C-1611F7082D05

Q35556797-25A1DCF0-7522-4E5F-AE72-DA46B5C1470A

Q35556797-271EE8FC-0A72-46BD-B640-E7658C32AFB1

Q35556797-2D2916EA-F67F-4F65-BD37-2E31CF5DCB9B

Q35556797-2DF169F0-80ED-4511-8CDF-C5880DC71B73

Q35556797-3789709C-AFF8-4086-A50D-110B3B3A6282

Q35556797-3F190C50-34E6-493A-BB45-7089E59489D1

Q35556797-4080A69D-EB39-4C96-8BCC-F91879E02742

Q35556797-42853F74-4D6C-40D5-A5B0-87F1FC04573B

P304

Q35556797-EA2F1C70-0570-40CB-9226-8DAA6D346062

P31

Q35556797-675CD860-1B32-45E4-B428-A9DFC4BFDFFC

P356

Q35556797-DD9D3B9D-E5A0-4D1B-AE6E-50950B82BF1C

P433

Q35556797-5C36B590-15FB-4AE8-A2EA-D8E04F65EE6C

P478

Q35556797-6AFFA5B1-ECCA-432C-A8D8-CE56C99FD33B

P577

Q35556797-5544F112-A997-4B82-9EBF-896C8D944171

P5875

Q35556797-0ADB83BA-2606-492A-87C8-54FB5BF1E618

P698

Q35556797-D3E1CC0A-77B2-4982-83F8-BEB49298EAFC

P921

Q35556797-480C6652-5D19-41AC-BFC9-E96E9B61CA37

P932

Q35556797-FF6BA45A-07D4-48EC-B97E-F83A27509922

P356

P1433

Monoclonal Antibodies

P1476

Highly specific off-target bin ...... tibody against FGF receptor 4.

@en

P2093

Anne Wong

http://www.w3.org/2001/XMLSchema#string

Arthur E Reyes

http://www.w3.org/2001/XMLSchema#string

Ben-Quan Shen

http://www.w3.org/2001/XMLSchema#string

Benjamin C Lin

http://www.w3.org/2001/XMLSchema#string

Daniela Bumbaca

http://www.w3.org/2001/XMLSchema#string

Elizabeth Drake

http://www.w3.org/2001/XMLSchema#string

Jean-Philippe Stephan

http://www.w3.org/2001/XMLSchema#string

Luc Desnoyers

http://www.w3.org/2001/XMLSchema#string

Mark S Dennis

http://www.w3.org/2001/XMLSchema#string

P2860

Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling

Antibody multispecificity mediated by conformational diversity

Role of Antibody Paratope Conformational Flexibility in the Manifestation of Molecular Mimicry

Structure and biology of complement protein C3, a connecting link between innate and acquired immunity

Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models

Test of a statistical model for molecular recognition in biological repertoires.

High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold.

Molecular basis for the binding promiscuity of an anti-p24 (HIV-1) monoclonal antibody.

Molecular basis for the binding polyspecificity of an anti-cholera toxin peptide 3 monoclonal antibody.

UPA, a universal protein array system for quantitative detection of protein-protein, protein-DNA, protein-RNA and protein-ligand interactions.

P304

376-386

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/MABS.3.4.15786

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2011-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51096503

http://www.w3.org/2001/XMLSchema#string

P698

21540647

http://www.w3.org/2001/XMLSchema#string

P921

P932

3218534

http://www.w3.org/2001/XMLSchema#string